개요
세계의 동물용 백신 시장은 2023년에 1억 2,400만 달러에 달하며, 2031년에는 2억 3,600만 달러에 달할 것으로 예측되며, 예측 기간인 2024-2031년 CAGR은 8.4%로 성장할 것으로 예측되고 있습니다.
동물용 백신은 특정 동물 질병에 대한 면역력을 제공하는 생물학적 제제입니다. 백신 접종은 동물의 건강 상태를 개선하고 인수공통전염병의 확산을 억제하며 우유, 육류, 계란, 양모 및 기타 관련 제품의 생산량을 늘리는 데 중요한 역할을 합니다.
동물용 백신에 대한 정부 구상 증가, 동물성 식품에 대한 수요 증가, 가축 질병 발생률 증가, 백신에 대한 동물의 인식 증가 등의 요인에 의해 시장이 주도되고 있습니다.
촉진요인
동물용 백신에 대한 정부 구상 증가
동물용 백신에 대한 정부 구상 증가세계 동물용 백신 수요는 여러 가지 요인에 의해 주도되고 있습니다. 주요 요인 중 하나는 동물용 백신에 대한 정부 구상이 증가하고 있다는 점입니다. 동물용 백신은 동물의 건강과 생산뿐만 아니라 안전한 식량 공급을 늘리고 동물에서 사람으로 전염되는 질병을 예방함으로써 사람의 건강에도 큰 영향을 미칩니다.
정부 기관과 동물 보호 단체는 다양한 노력과 프로그램을 통해 동물 백신 사용을 적극적으로 장려하고 있으며, 이는 이 시장의 성장을 가속하고 있습니다. 예를 들어 2023년 9월, 정부는 구제역(FMD) 백신 프로그램에 따라 2025년까지 구제역을 봉쇄하고 2030년까지 근절하기 위해 13,000 crores 이상의 예산을 책정했습니다. 이 프로그램은 소, 버팔로, 양, 염소, 염소, 돼지의 100%에 구제역 백신을 접종하고 생후 4-8개월된 암송아지 100%에 백신을 접종하는 것을 목표로 하고 있습니다.
또 2022년 6월, 농업 및 농민 복지부 장관은 하리아나 주 히사르에 위치한 ICAR-국립 말 연구센터가 개발한 동물 백신 및 기타 진단 키트를 출시했습니다.
또한 동물용 백신을 사람들에게 인식시키기 위한 새로운 플랫폼 도입과 같은 정부 전략은 이 시장의 성장을 가속할 것으로 보입니다. 예를 들어 2023년 6월 연방 장관은 동물용 의약품 및 백신 신청을 처리하고 이의제기 없음 인증(NOC)을 부여하기 위해 Nandi 포털을 개설했습니다. 동물용 의약품과 백신의 수입, 제조, 판매에 대한 규제는 보건부 산하 중앙의약품표준관리기구(CDSCO)의 관할 하에 있습니다.
마찬가지로 2022년 8월, 인도 찬디가르 행정청 축산국은 펀자브와 할리야나 주에서 소의 피부병이 발생했고 찬디가르에서도 드문 사례가 보고됨에 따라 동물병원에서 예방접종을 시작하기로 결정했습니다.
억제요인
높은 백신 보관 및 유지 비용, 백신 관련 부작용, 엄격한 규제 요건, 백신 기술 가용성 제한, 백신 제조의 복잡성, 높은 동물용 백신 연구개발(R&D) 비용 등의 요인이 시장을 저해할 것으로 예상됩니다.
Overview
The global veterinary vaccines market reached US$ 124 million in 2023 and is expected to reach US$ 236 million by 2031, growing at a CAGR of 8.4% during the forecast period 2024-2031.
A veterinary vaccine is a biological preparation that provides immunity against a particular animal disease. Vaccination plays a crucial role in improving animal health, reducing the spread of zoonotic diseases, and increasing the production of milk, meat, eggs, wool, and other related products.
The market is driven by factors such as the increasing government initiatives for veterinary vaccines, the rising demand for animal-derived food products, the increasing incidence of livestock diseases, and the growing population of animal's awareness of vaccines.
Market Dynamics: Drivers
Increasing Government Initiatives for Veterinary Vaccines
The demand for the global veterinary vaccines market is driven by multiple factors. One of the key factors is the increasing government initiatives for veterinary vaccines. Veterinary vaccines have a major impact not only on animal health and production but also on human health through increasing safe food supplies and preventing animal-to-human transmission of infectious diseases.
Government agencies and animal welfare organizations are actively promoting the use of veterinary vaccines through various initiatives and programs to drive this market growth. For instance, in September 2023, under the FMD (Food and Mouth Disease) vaccine program, the government earmarked more than 13,000 crores intending to contain the disease by 2025 and eradicate it by 2030. The program aims to vaccinate 100% of cattle, buffalo, sheep, goat, and pig population for FMD and 100% of bovine female calves of 4-8 months of age.
Also, in June 2022, the Union Minister of Agriculture & Farmers' Welfare launched animal vaccines and other diagnostic kits developed by the ICAR-national Research Center on Equines, Hisar, Haryana.
Moreover, government strategies such as introducing new platforms to aware people of veterinary vaccines would propel this market growth. For instance, in June 2023, the Union Minister launched a Nandi portal to process applications and grant non-objection certification (NOC) for veterinary drugs and vaccines. The regulation of the import, manufacturing, and marketing of veterinary drugs and vaccines comes under the purview of the Central Drug Standard Control Organization (CDSCO) under the Ministry of Health.
Similarly, in August 2022, The Department of Animal Husbandry, Chandigarh Administration (India), has decided to start immunization in veterinary facilities because of the ongoing lumpy skin disease outbreak among cattle in Punjab and Haryana as well as rare instances being reported from Chandigarh.
Restraints
Factors such as the high storage & maintenance cost of vaccines, side-effects associated with the vaccines, stringent regulatory requirements, limited availability of vaccine technologies, complexity of vaccine manufacturing, and high cost of research and development (R&D) of veterinary vaccines are expected to hamper the market.
The global veterinary vaccines market is segmented based on the vaccine, type, route of administration, distribution channel, and region.
The canine vaccines segment accounted for approximately 56.5% of the global veterinary vaccines market share
The canine vaccines segment is expected to hold the largest market share over the forecast period. The increasing number of pet dogs globally, the growing demand for animal health care, and the increasing awareness of zoonotic diseases drive this segment's growth.
Moreover, ongoing advancements in research and development contribute to the growth of the segment. For instance, in February 2024, The University of Pennsylvania (Penn) School of Veterinary Medicine (Penn Vet) announced the launch of the school's mRNA research initiative to fast-track the development of veterinary mRNA-based vaccines and host-directed therapies.
Also, in March 2024, the Zendal group launches a CSIC-developed vaccine against canine leishmaniasis. A team formed by the Zendal group and scientists from the Spanish National Research Council developed in 2022 the first vaccine for animal mammals based on recombinant DNA to fight canine leishmaniasis, a parasite that causes from skin ulcers to severe inflammation of the liver and spleen.
In addition, key players in the market introducing the rising launches of canine vaccines help to propel this segment's growth in the market. For instance, in June 2024, MSD Animal Health announced the launch & availability of NOBIVAC NXT Rabies in Canada first-of-its-kind line of vaccines that leverages state-of-the-art RNA-particle technology to protect cats and dogs from rabies.
Also, in September 2022, Merck Animal Health announced the domestic launch of the first oral Bordetella bronchiseptica and canine parainfluenza virus vaccine with mucosal protection and easy oral administration.
North America accounted for approximately 41.2% of the global veterinary vaccines market share
North America region is expected to hold the largest market share over the forecast period owing to the high prevalence of livestock and zoonotic diseases, rising demand for livestock-based products and animal-derived food products drives this market growth in this region.
In addition, the rising incidence of canine disorders, which is increasing the adoption of veterinary vaccination, and the rising number of pet insurance in the region are expected to propel this market growth. According to the American Pet Insurance Statistics in September 2023, in the US, 5.36 million pets are insured by their owners, in comparison to over 86.9 million pet-owning households across the country.
Moreover, key players in this region more focus on developing veterinary vaccines for infectious diseases, and government initiatives would propel this market growth. For instance, in March 2023, a joint initiative between the Biotechnology and Biological Sciences Research Council (BBSRC), part of UK Research and Innovation (UKRI), the Foreign, Commonwealth and Development Office (FCDO), and the Bill & Melinda Gates Foundation will see the creation of a new center at The Pirbright Institute designed to accelerate the development of animal vaccines to combat emerging and urgent infectious diseases.
Also, in April 2024, the United States Government, through the United States Agency for International Development (USAID), donated 100,000 doses of the anthrax vaccine in support of the Government of Ghana and the U.N. Food and Agriculture Organization's (FAO) anthrax vaccination campaign.
In addition, major players in the industry introducing newer vaccines for infectious diseases help to drive this market growth in this region, For instance, in June 2023, Boehringer Ingelheim Animal Health Canada Inc. launched a vaccine combination that delivers protection against two of the most devastating and economically damaging swine diseases in one shot. FLEX CircoPRRS protects pigs against porcine circovirus 2 (PCV2) and porcine reproductive and respiratory syndrome (PRRSv).
By Route of Administration
The major global players in the veterinary vaccines market include Merck & Co., Inc, Zoetis Services LLC, Boehringer Ingelheim International GmbH, Biogenesis Bago, Elanco, Ceva, HESTER BIOSCIENCES LIMITED, Phibro Animal Health Corporation, Indian Immunologicals Ltd, and CZ Vaccines among others.
The global veterinary vaccines market report would provide approximately 70 tables, 75 figures, and 182 Pages.
Target Audience 2024
LIST NOT EXHAUSTIVE